CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Publications

Leukemia & lymphoma, Nov 2021 |

1-5

DOI:

10.1080/10428194.2021.1986219

Duell, Johannes; Obr, Aleš; Augustin, Marinela; Endell, Jan; Liu, Hao; Geiger, Sabine; Silverman, Ian M; Ambarkhane, Sumeet; Rosenwald, Andreas

Product Used

NGS

Read Full Article

Product Used

NGS

Genes